New combo therapy aims to delay prostate cancer progression

NCT ID NCT04070209

Ongoing Disease control Sponsor: Sir Mortimer B. Davis - Jewish General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding precise radiation (SBRT) to the hormone therapy darolutamide can delay cancer progression in men with castration-resistant prostate cancer that has only a few new spots of growth. The study involves 66 participants and measures how long it takes for the cancer to worsen. The goal is to postpone the need for stronger, more aggressive treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: darolutamide (a hormone therapy drug) and stereotactic body radiotherapy (SBRT, a precise type of radiation)
What this could lead to: If successful, this approach could delay the need for stronger second-line treatments and help men with prostate cancer maintain a better quality of life for longer.
What could go wrong: This is a small, early-phase pilot study with only 66 participants, so results may not apply to all patients. There is also a risk that the combination may not improve progression-free survival or could cause side effects from radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Centre hospitalier affilié universitaire régional (CHAUR)

Trois-Rivières, Quebec, G8Z 3R9, Canada
Centre hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, H2X 3E4, Canada
Centre of Applied Urology Research

Halifax, Nova Scotia, B3H 2Y9, Canada
Hôpital Fleurimont (CHUS)

Sherbrooke, Quebec, J1H 5N4, Canada
Hôpital Maisonneuve-Rosemont

Montreal, Quebec, H1T 2M4, Canada
Hôpital de Gatineau

Gatineau, Quebec, J8P 7H2, Canada
L'Hôtel-Dieu de Québec (CHUQ)

Québec, Quebec, G1R 2J6, Canada
Prostate Cancer Centre

Calgary, Alberta, T2V 1P9, Canada
Service d'urologie et Centre de la prostate

Longueuil, Quebec, J4V 2H3, Canada
Sir Mortimer JGH

Montreal, Quebec, H3T 1E2, Canada
St. Joseph's Healthcare Hamilton

Hamilton, Ontario, L8N 4A6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.